These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35599598)

  • 21. Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System.
    Chen C; Fu F; Ding L; Xiao J
    J Clin Pharm Ther; 2022 Nov; 47(11):1789-1795. PubMed ID: 36089844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
    Miller ER; McNeil MM; Moro PL; Duffy J; Su JR
    Vaccine; 2020 Nov; 38(47):7458-7463. PubMed ID: 33039207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.
    Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
    Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza vaccination and Guillain Barre syndrome.
    Geier MR; Geier DA; Zahalsky AC
    Clin Immunol; 2003 May; 107(2):116-21. PubMed ID: 12763480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports.
    Riad A; Põld A; Kateeb E; Attia S
    Front Public Health; 2022; 10():952781. PubMed ID: 35899169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety profile of COVID-19 vaccinations in the United States.
    Singh A; Khillan R; Mishra Y; Khurana S
    Am J Infect Control; 2022 Jan; 50(1):15-19. PubMed ID: 34699960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guillain-Barré syndrome following influenza vaccination.
    Haber P; DeStefano F; Angulo FJ; Iskander J; Shadomy SV; Weintraub E; Chen RT
    JAMA; 2004 Nov; 292(20):2478-81. PubMed ID: 15562126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
    Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
    J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
    Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
    Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
    Su JR; McNeil MM; Welsh KJ; Marquez PL; Ng C; Yan M; Cano MV
    Vaccine; 2021 Jan; 39(5):839-845. PubMed ID: 33422381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines.
    Sessa M; Kragholm K; Hviid A; Andersen M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1451-1453. PubMed ID: 34264151
    [No Abstract]   [Full Text] [Related]  

  • 37. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010-2017.
    Hibbs BF; Ng CS; Museru O; Moro PL; Marquez P; Woo EJ; Cano MV; Shimabukuro TT
    Vaccine; 2020 Jan; 38(5):1137-1143. PubMed ID: 31784231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis.
    Santi Laurini G; Montanaro N; Motola D
    Eur J Clin Pharmacol; 2023 May; 79(5):657-661. PubMed ID: 36961579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
    Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
    Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.